Optheras is developing a laser technology that utilizes photothermal coagulation to treat non-invasive Ta low-grade bladder tumors in an office setting, eliminating the need for general anesthesia and reducing patient discomfort. This approach addresses the high recurrence rates and frequent surgical interventions associated with bladder cancer, improving patient quality of life and healthcare efficiency.
Funding
Funding not disclosed
Founders
Product
Problem
Non-muscle invasive bladder cancer (NMIBC) has a high recurrence rate, often requiring frequent surveillance, repeat surgeries performed under general anesthesia, and hospitalizations. The current gold standard treatment, Transurethral Resection of Bladder Tumor (TURBT), is costly and can reduce a patient's quality of life due to the need for repeat procedures.
Solution
Optheras is developing a laser technology for the management of non-muscle invasive bladder cancer, specifically Ta low-grade tumors. The laser system utilizes photothermal coagulation to achieve immediate and effective tumor necrosis. Designed for use in office and outpatient settings, the technology aims to provide a less invasive and low-pain treatment option, eliminating the need for general anesthesia. The goal is to offer a resource and cost-efficient procedure that is safe for both patients and medical professionals, while also being non-inferior to TURBT.
Target Audience
The primary target audience includes urologists and medical professionals seeking an alternative to traditional TURBT for treating Ta low-grade bladder cancer in an office setting.
Features
- Photothermal coagulation for tumor necrosis
- Designed for use in an office or outpatient setting, eliminating the need for general anesthesia
- Flex-scope compatible with single and re-useable cystoscopes
- Real-time target guidance and power adaption to the surgical situation
- Highly flexible disposable fiber
- Silent and energy-efficient wheelable unit